ALKS · Alkermes plc.

Track ALKS — free

$50.18 +0.70 (+1.41%) At close · Aug 19

Market Cap

$8.30B

167.76M

Up next

Next earnings call

Oct 21, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 28, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Moderate

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +37%

above

Price vs 50-day avg +0%

above

RSI (14) 52

neutral

MACD trend Negative

52-week position 82%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −5%

trailing

6-month return +63%

trailing

YTD return +79%

this year

Relative strength +52%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $50 › 200d $37 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +91 funds added

Insider flow Distributing

Net -$2.9M over 90 days · 100% sells

Short interest Falling

8.59% of float · ▼ -4.1% MoM · 7.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

422 holders — near 3-yr high, broad support

Squeeze score 63

elevated · 0–100

Fundamentals

Fair

Revenue growth −5%

Y/Y

EPS growth −34%

Y/Y

Free cash flow $480.3M

Valuation P/E 130.2

rich

Buyback $172.3M

remaining

Balance sheet $388.6M

net cash

Quant / Vol

risk profile

Moderate

Volatility 41%

annualized · 1-yr

Max drawdown −22%

past year

ATR 3.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 28, 2026

2026 Expectations

Total Revenues $1.73B – $1.84B

VIVITROL Net Sales $460M – $480M

ARISTADA Net Sales $365M – $385M

LYBALVI Net Sales $380M – $400M

Cost of Goods Sold $320M – $340M

R&D Expenses $445M – $485M

Amortization of Intangible Assets $75M – $85M

SG&A Expenses $890M – $930M

Change in the Fair Value of Contingent Consideration $25M

Net Tax Benefit $0

Net Interest Expense $75M – $85M

GAAP Net Loss $-115M – $-95M

EBITDA $75M – $95M

Adjusted EBITDA $370M – $410M

Feb. 12, 2026 – Dec. 31, 2026

LUMRYZ Net Sales $315M – $335M

Prior guidance period ended · from the 8-K filed Oct 28, 2025

Effective Tax Rate · year ending December 31, 2025 17%

VIVITROL net sales · year ending Dec. 31, 2025 $460M – $470M

ARISTADA net sales · year ending Dec. 31, 2025 $360M – $370M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+37% Bullish

Price vs 50-day avg

+0% Bullish

RSI (14)

52 Neutral

MACD trend

Negative Bearish

52-week position

82% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $50 › 200d $37 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +91 funds added

Insider flow Distributing

Net -$2.9M over 90 days · 100% sells

Short interest Falling

8.59% of float · ▼ -4.1% MoM · 7.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

422 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $27 Now $50 · 82% Range high $55

vs 200-day avg +37% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$219.5M	Six Months Ended June 30, 2026	—

GAAP → non-GAAP reconciliation GAAP Net (Loss) Income — GAAP -65.98M -13.88M Interest income +46.82M Interest expense +2.18M Income tax provision +15.45M Depreciation expense +34.26M Amortization of acquired intangible assets +85.88M Share-based compensation +88.35M Costs related to the acquisition of Avadel +26.41M Change in the fair value of contingent consideration = Adjusted EBITDA 219.48M
ARISTADA net sales	$96.7M	Q2’26	-4.5%

LUMRYZ net sales	$96.6M	Q2’26	—

LYBALVI gross-to-net deductions	36%	Q2’26	—
LYBALVI net sales	$94M	Q2’26	+11.5%

Total Proprietary Net Sales	$749.8M	Six Months Ended June 30, 2026	—

VIVITROL net sales	$124.5M	Q2’26	+2.3%

EBITDA From Continuing Operations	$285.6M	Twelve Months Ended December 31, 2025	—
GAAP → non-GAAP reconciliation GAAP Net Income from Continuing Operations 241.66M +27.09M Depreciation expense +75K Amortization expense -45.3M Interest income +12.28M Interest expense +49.79M Income tax provision = EBITDA 285.59M
LYBALVI revenue growth	22%	the fourth quarter of 2025	—
LYBALVI total prescriptions growth	25%	the fourth quarter of 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ALKS Alkermes plc. this stock	$8.30B	+79.3%	-5.2%	130.2	8.6%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$64.91B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$57.75B	+17.6%	—	—	0.1%
GALDY Galderma Group AG/ADR	$50.24B	+4.0%	—	—	0.0%
HLN Haleon plc	$43.41B	-2.4%	—	—	0.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

422

% held: 106.9%
Net QoQ: +2.5M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

159

View

Short & Settlement

Short Interest Falling

Shares short

14.4M

Days to cover: 7.7d
Change: -610.8K sh

View

Short Volume

Short vol %

17%

As of: Aug 19, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.0K
As of: Jul 29, 2026

View

Off-Exchange

Off-exchange %

36.3%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$2.9M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$1.5B

Net income (FY): $241.7M
EPS diluted: $1.43

View

Buybacks

Authorized

$400.0M

Remaining: $172.3M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 19

View

Proposed Sales

Value

$372.9K

Shares: 7.6K
Filed: Aug 17, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 28, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ALKS	-0.2%	-4.6%	+63.3%	+2.4%	+79.3%
SPY	-0.4%	+2.9%	+11.6%	+3.0%	+12.8%
vs SPY	+0.2%	-7.5%	+51.7%	-0.5%	+66.6%

Capital returns

Buyback program · as of Jun 30, 2026

Authorized

$400.00M

Spent (derived)

$227.70M

Remaining

$172.30M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1520262 CUSIP G01767105 13F (30d) 398 filings 379 filers Visit website Investor relations

ALKS · Alkermes plc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns